Eikon Therapeutics to Participate in Cantor KOL PARP-Inhibitor Event
Eikon Therapeutics (EIKN) says it will participate in a KOL event on the therapeutic use of PARP inhibitors in oncology hosted by Cantor Fitzgerald.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.